Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?

Author(s): Georgios V. Koukourakis

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery
Continued as Recent Advances in Inflammation & Allergy Drug Discovery

Volume 9 , Issue 2 , 2015


Recently, the improvement of innovative medications named focused treatments represents the consequence of a superior knowledge of the procedures implicated in the modification of physiological tissues in tumor. Focused treatment is known as the therapy which uses specific substances that affect selective mechanisms implicated in tumorigenesis and tumor development. Angiogenesis is important for tumor development and distant metastatic disease and represents a significant aim for modern biological substances. Bevacizumab belongs to humanized recombinant antibody family which obviates vascular endothelial growth factor (VEGF) receptor fastening, and suspending genesis of new vessels and tumor development. Bevacizumab represents the primary antiangiogenic treatment authorized for usage in tumor and has FDA authorization to treat the recurrent glioblastoma multiform since 2009. Bevacizumab’s efficiency for treating malignant brain gliomas along with correlated patent appliances related to this agent is discussed below.

Keywords: Avastin, bevacizumab, chemotherapy, glioblastoma multiforme, malignant brain gliomas, radiation therapy, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [136 - 143]
Pages: 8
DOI: 10.2174/1872213X09666150807110031
Price: $65

Article Metrics

PDF: 29